1092

EARLY LIFE EXPOSURE TO AGRICULTURE AND BIODIVERSITY INFLUENCES CROHN’S DISEASE RISK IN A POPULATION-BASED COHORT STUDY

Date
May 21, 2024
Explore related products in the following collection:

Background
Specific pollutants and environmental exposures are implicated in modulating inflammatory bowel disease (IBD) risk. Crohn’s disease (CD) clustering has been reported in agricultural areas. However, the role of environmental exposures, particularly in early life, towards IBD risk, has not been systematically evaluated.

Methods
We conducted a nationwide population-based cohort study during the study period extending from January 1, 1995, to September 1, 2020, using cross-linked Danish registers, maps, and inventories to ascertain the impact of agricultural land use, biodiversity, green space, urban space, blue space, and natural vegetation density index during pregnancy and the first two years of life on IBD, CD, and ulcerative colitis (UC) risk, using adjusted Cox proportional hazards regression analyses. We adjusted for the following covariates: sex, maternal age at delivery, calendar year of birth, municipal-level socioeconomic status, and first-degree relative with IBD.

Results
Of 1,438,487 individuals included in the study who were followed from age 2 years until a median (IQR) age of 14 (8-20) years, 3,768 individuals were diagnosed with IBD. Exposure to the highest and third quartiles of agriculture land use during early life, relative to the lowest quartile, were associated with increased IBD risk (aHR 1.16, 95% CI 1.02, 1.31 and 1.19, 95% CI 1.07, 1.32, respectively). Conversely, exposure to the highest and third quartiles of biodiversity in early life, compared to the lowest quartile, were associated with a lower IBD risk (aHR 0.90, 95% CI 0.82, 1.00 and 0.90, 95% CI 0.82, 0.99, respectively). These associations were driven by differences in CD risk (Figure), but there was no association with UC risk. Other environmental exposures were not associated with IBD risk.

Conclusion
In a nationwide cohort with long-term follow up data, early life exposure to agriculture land use was associated with an increase in CD risk, while higher biodiversity was protective.

Speakers


Tracks

Related Products

Thumbnail for NATURAL HISTORY OF PRESUMED ISOLATED CROHN'S DISEASE PERIANAL FISTULA
NATURAL HISTORY OF PRESUMED ISOLATED CROHN'S DISEASE PERIANAL FISTULA
Approximately 20% of patients with Crohn’s disease (CD) have perianal fistulizing CD, which are most often complex perianal fistula (PAF). Studies have shown that 4-5% of patients with CD present with PAF without luminal disease, termed isolated perianal CD (iPCD)…
Thumbnail for CHARACTERIZING EPITOPES AND ISOTYPES OF CROHN'S DISEASE-ASSOCIATED ANTI-GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR ANTIBODIES.
CHARACTERIZING EPITOPES AND ISOTYPES OF CROHN'S DISEASE-ASSOCIATED ANTI-GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR ANTIBODIES.
Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) maintains mononuclear phagocytes (MNP) and supports intestinal immune homeostasis. Anti-GM-CSF autoantibodies (aGMAbs) are found in approx. 25% of all Crohn’s disease (CD) patients…
Thumbnail for SIMPLE ENDOSCOPIC SCORE FOR CROHN’S DISEASE (SES-CD) ≥ 7 PREDICTS DISEASE PROGRESSION IN PATIENTS WITH MILD CD
SIMPLE ENDOSCOPIC SCORE FOR CROHN’S DISEASE (SES-CD) ≥ 7 PREDICTS DISEASE PROGRESSION IN PATIENTS WITH MILD CD
Approximately 20-30% of individuals with Crohn's disease (CD) experience a relatively mild disease course without progression. However, there is no widely accepted objective definition of mild CD. We aimed to identify endoscopic severity cut-offs that can be used to define mild non-progressive CD…
Thumbnail for DISEASE CLEARANCE AFTER 16 WEEKS OF TREATMENT WITH VEDOLIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM THE VERDICT TRIAL
DISEASE CLEARANCE AFTER 16 WEEKS OF TREATMENT WITH VEDOLIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM THE VERDICT TRIAL
BACKGROUND: Disease clearance in ulcerative colitis (UC) is defined as concurrent achievement of clinical, endoscopic, and histologic remission…